Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Treatment of cancer
Niraparib/abiraterone acetate
Другие языки:

    Niraparib/abiraterone acetate

    Подписчиков: 0, рейтинг: 0

    Niraparib/abiraterone acetate
    Combination of
    Niraparib Antineoplastic agent
    Abiraterone acetate Hormone antagonist
    Clinical data
    Routes of
    administration    		 By mouth
    ATC code
    • None

    Niraparib/abiraterone acetate is an experimental combination anti-cancer medication under investigation for the treatment of prostate cancer. It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist).

    Society and culture

    Legal status

    On 23 February 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Akeega, intended for the treatment of adults with metastatic castration-resistant prostate cancer with BRCA 1/BRCA 2 mutations. The applicant for this medicinal product is Janssen-Cilag International N.V.



    Новое сообщение